In a 69‑year‑old man with newly diagnosed Parkinson’s disease, normal routine blood results, no prior fractures and no history of kidney stones, should he be started on bone‑protective therapy according to UK guidelines?

Bone Protection in Newly Diagnosed Parkinson's Disease

Yes, this 69-year-old man with newly diagnosed Parkinson's disease should undergo formal fracture risk assessment, and based on UK guidelines, he likely warrants bone-protective therapy even without prior fractures.

Why Fracture Risk Assessment is Essential

According to the most recent 2025 systematic review of osteoporosis management in Parkinson's disease, people with Parkinson's have a fracture burden that exceeds other common causes of secondary osteoporosis such as COPD, type 1 diabetes, and multiple sclerosis 1. The evidence explicitly recommends that patients with Parkinson's should have a fracture-risk assessment 1.

UK-Specific Risk Assessment Tools

For UK practice, QFracture is particularly recommended because:

• It is based on UK population data 1
• It includes Parkinson's disease as a specific clinical risk factor 1
• It can calculate 1- to 10-year fracture probabilities (not just 10-year like FRAX) 1
• FRAX significantly underestimates fracture probability in people with Parkinson's 1

The BONE-PARK algorithm, which integrates National Osteoporosis Guideline Group (NOGG) guidance specifically for Parkinson's patients, should guide your management 1.

Immediate Steps to Take

1. Perform Fracture Risk Assessment

• Calculate QFracture score (includes PD as a risk factor)
• Assess for falls in the past year (critical in PD patients)
• Consider DEXA scan for bone mineral density measurement 2

2. Initiate Baseline Bone Protection NOW

Even before formal risk stratification results, start vitamin D supplementation immediately 1:

• Vitamin D deficiency is extremely common in Parkinson's disease
• Vitamin D is crucial not only for bone health but also for substantia nigra cell function 3
• Consider weekly or monthly dosing schedules given potential future swallowing difficulties 1

3. Optimize Nutrition

• Ensure adequate protein intake: 1.0-1.2 g/kg body weight per day 1
• Address calcium intake (though NICE NG71 cautions about cardiovascular concerns with supplements, NOGG supports supplementation when dietary intake is inadequate) 1

Treatment Considerations Based on Risk Assessment Results

If Fracture Risk is Above NOGG Intervention Thresholds:

First-line options in order of preference for Parkinson's patients:

1. Intravenous zoledronic acid (annually for 3 years) - Most practical option 1

   • 40% reduction in nonvertebral fractures
   • 75% reduction in vertebral fractures
   • Avoids daily medication adherence issues
   • No concerns about dysphagia or gastroparesis

2. Denosumab (subcutaneous every 6 months) 1

   • Good alternative if IV access problematic
   • Caution: Risk of rebound vertebral fractures if discontinued
   • Monitor calcium levels (risk of hypocalcemia, especially with renal impairment)

3. Oral bisphosphonates - Less ideal in PD 1

   • Alendronate, risedronate, or ibandronate
   • Major limitation: Strict dosing requirements (empty stomach, upright position for 30+ minutes, fasting)
   • Problematic with dysphagia, gastroparesis, and complex PD medication schedules
   • Monthly formulations (e.g., ibandronate) slightly better than daily

Critical Parkinson's-Specific Considerations

Why Standard Approaches Don't Work Well:

Parkinson's disease creates unique barriers to standard osteoporosis treatment 1:

• Dysphagia - makes oral bisphosphonates difficult
• Gastroparesis/slow gut motility - affects absorption
• Cognitive impairment - affects medication adherence
• Complex medication regimen - adding daily medications is problematic
• Postural instability - maintaining upright position for 30 minutes post-bisphosphonate is challenging

The Fall Risk Factor

Even with normal bone density, Parkinson's patients have elevated fracture risk due to falls 2:

• 40.7% of PD patients report recurrent falls within the first year 2
• Falls are not adequately captured in standard FRAX calculations 1
• This is why PD-specific algorithms are essential

Common Pitfalls to Avoid

1. Don't wait for a fracture - 28% of PD patients already have prior fragility fractures at baseline 2
2. Don't rely solely on FRAX - it underestimates risk in Parkinson's 1
3. Don't prescribe daily oral bisphosphonates without considering PD-specific barriers 1
4. Don't forget vitamin D - it has dual benefits for bone and neurological function 3
5. Don't ignore the levodopa-protein interaction - ensure adequate protein despite this competition 1

Monitoring Hyperhomocysteinemia

Check homocysteine levels, as levodopa therapy causes hyperhomocysteinemia, which is an independent risk factor for osteoporosis 3. Consider vitamin B12 and folic acid supplementation if elevated.

The neurologist is correct to raise this concern early - bone health should be addressed at diagnosis, not after the first fracture, given the substantially elevated risk in Parkinson's disease.